Head: Dr. Antonello Vidiri, MD
STAFF

Radiomic: involves the analysis and translation of medical images into quantitative data with the underlying hypothesis that imaging reflects not only macroscopic but also the cellular and molecular properties of tissues. The objective of radiomics is to generate image-driven biomarkers that serve as instruments that provide a deeper understanding of cancer biology to better aid clinical decisions. We are using this techinique in lung, in patients underwent surgery, in head and neck in the differentation of parotid tumor and in liver tumors, in patients with metastases from colon carcinoma underwent surgery after chemotherapy.

Radiogenomic: field of research aimed at developing tools for non-invasive genotyping by identifying imaging biomarkers for genomic subtypes. Radiogenomic analysis refers to the integration of radiophenothypes and genomic data in order to find radiogenomic association. A correlation study is underway between CT radiomic features and specific drivers mutational status of NSCLC.

In Head and Neck tumors underwent surgery we investigate the correlation between the parameters identified by perfusion imaging (neo-vascularization) and diffusion (cellularity and stroma) with those of the immunohistochemistry and digital pathology, RNASEQ, and with the immunoprofiling of the cells of the immune system in the periphery.

Investigate the possibility to obtaine before treatment diagnostic elements predictive of the response to treatment.

Multiparametric-MR prostate studies before and after therapy, in particular in the evaluation of the alterations after radiotherapy compared with those PET-CT scan.

Neo-adjuvant treatments using 3T MR with functional sequences (diffusion and perfusion) in the sarcomas, osteosarcoma and Ewing sarcoma.

In the Interventional service we use targeted therapy dosimetry - guided that may significantly impact on patient’s specific therapy selection and treatment.

In the brain tumors we are investigating correlation between MR imaging with those pathological date and molecular profile (Glioma Project).